Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arrowhead Pharmaceuticals (ARWR)

Tipranks - Tipranks - Wed Apr 22, 4:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Arrowhead Pharmaceuticals (ARWR) with bullish sentiments.

Claim 30% Off TipRanks

Eli Lilly & Co (LLY)

In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1350.00. The company’s shares closed last Monday at $919.90.

According to TipRanks.com, Field is a 3-star analyst with an average return of 1.4% and a 42.9% success rate. Field covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. ;'>

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1247.71, which is a 34.6% upside from current levels. In a report issued on April 7, TipRanks – xAI also upgraded the stock to Buy with a $1038.00 price target.

See the top stocks recommended by analysts >>

Arrowhead Pharmaceuticals (ARWR)

In a report released today, Michael Ulz from Morgan Stanley upgraded Arrowhead Pharmaceuticals to Buy, with a price target of $100.00. The company’s shares closed last Monday at $69.25.

According to TipRanks.com, Ulz is a 3-star analyst with an average return of 2.2% and a 44.5% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Rhythm Pharmaceuticals, and Rocket Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $97.33 average price target, a 40.6% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $93.00 price target.

Read More on LLY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).